Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells

Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells

Abstract Background Multiple studies concluded that oncometabolites (e.g. D-2-hydroxyglutarate (2-HG) related to mutant isocitrate dehydrogenase 1/2 (IDH1/2) and lactate) have tumour promoting potential. Regulatory mechanisms implicated in the maintenance of oncometabolite production have great inte...

Full description

Bibliographic Details
Main Authors: Zoltán Hujber, Gábor Petővári, Norbert Szoboszlai, Titanilla Dankó, Noémi Nagy, Csilla Kriston, Ildikó Krencz, Sándor Paku, Olivér Ozohanics, László Drahos, András Jeney, Anna Sebestyén
Format: Article
Language:English
Published: BMC 2017-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Rapamycin
mTOR
Oncometabolite
2-hydroxyglutarate
Lactate
Tumour metabolism
Online Access:http://link.springer.com/article/10.1186/s13046-017-0544-y

Internet

http://link.springer.com/article/10.1186/s13046-017-0544-y

Similar Items